Silo Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on January 9, 2024. The report discloses a corporate action approved by the Board of Directors on the same date regarding the company's capital management strategy.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on a corporate governance event.
Material Changes
The primary material event reported is the extension of the Company's stock repurchase program. The Board authorized the purchase of up to $1 million of the Company's common stock, extending the program's deadline to March 31, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks and contingencies beyond the standard disclosure of the repurchase program extension.
Key Facts for Investor Verification
- Stock repurchase program authorization amount: $1 million.
- New expiration date for the repurchase program: March 31, 2024.
- Trading symbol: SILO on The Nasdaq Stock Market LLC.
- The filing does not disclose the number of shares previously repurchased or the current cash balance available for the program.